Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27:28:1610315.
doi: 10.3389/pore.2022.1610315. eCollection 2022.

High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer

Nándor Polk  1 , Barna Budai  2 , Erika Hitre  3 , Attila Patócs  2   4   5 , Tamás Mersich  1
Affiliations

High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer

Nándor Polk et al. Pathol Oncol Res. .

Erratum in

Abstract

Background: The literature data regarding colon cancer patients with liver-only metastases (CLM) show that NLR determined before metastasectomy is a prognostic marker of shorter relapse-free survival (RFS), but no results has been reported to date for rectal cancer patients with liver-only metastases (RLM). This study aimed to investigate the NLR and SII in CLM and RLM. Methods: Relapse-free (RFS) and overall survival (OS) were evaluated in 67 CLM and 103 RLM patients with a median follow-up of 46.5 and 59.8 months, respectively. Pre- and/or postoperative chemotherapy ± targeted treatment was applied in 96% and 87% of CLM and RLM patients, respectively. The cut-off level for hematologic parameters were determined by receiver operating characteristic (ROC) analysis. Univariate analysis was performed by Kaplan-Meier method and log rank test. For multivariate analysis Cox regression was applied. Results: In univariate analysis low NLR (cut-off 2) and SII (535) were predictors of longer RFS in case of CLM (p < 0.01). In contrast, for RLM high NLR (2.42) and SII (792) were predictors of longer RFS (p < 0.001). For RLM both NLR and SII proved to be independent markers of RFS (HR 0.66 (95% CI 0.52-0.84) and 0.73 (0.57-0.91), respectively) and OS (0.76 (0.58-0.99) and 0.66 (0.5-0.87), respectively). Only NLR (1.44 (1.04-1.99)) was independent marker of RFS for CLM. The preoperative treatment has not influenced the role of NLR or SII. Conclusion: In contrast to CLM, in RLM the high NLR or SII determined before metastasectomy proved to be independent prognostic factors of longer RFS and OS.

Keywords: liver-only metastases of colon cancer; liver-only metastases of rectal cancer; metastasectomy; neutrophil-to-lymphocyte ratio; preoperative treatment; relapse-free survival; systemic immune-inflammation index.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Relapse-free survival (RFS) after liver metastasectomy of patients with rectal cancer (A,B) and colon cancer (C,D) according to neutrophil-to-lymphocyte ratio (NLR) (A,C) and systemic immune-inflammation index (SII) (B,D).
FIGURE 2
FIGURE 2
Relapse-free survival (RFS) after liver metastasectomy of patients with rectal cancer according to neutrophil-to-lymphocyte ratio (NLR) (A,B) and systemic immune-inflammation index (SII) (C,D) and according to treatment: no treatment (A,C) or chemotherapy (±targeted treatment) before metastasectomy (B,D).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin (2021) 71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Liu W, Zhang W, Xu Y, Li Y-H, Xing B-C. A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in This Modern Era. Ann Surg Oncol (2021) 28:7709–18. 10.1245/s10434-021-10143-6 - DOI - PubMed
    1. Alabraba E, Ibrahim H, Olaru A, Cameron I, Gomez D, Group NHS. Retrospective Cohort Study of Statin Therapy Effect on Resected Colorectal Liver Metastases. Wjgs (2020) 12:34–44. 10.4240/wjgs.v12.i2.34 - DOI - PMC - PubMed
    1. Dupré A, Jones RP, Diaz-Nieto R, Fenwick SW, Poston GJ, Malik HZ. Preoperative Leucocyte-Based Inflammatory Scores in Patients with Colorectal Liver Metastases: Can We Count on Them? World J Surg (2019) 43:1351–9. 10.1007/s00268-019-04914-2 - DOI - PubMed
    1. Kim W-J, Lim T-W, Kang S-H, Park P-J, Choi S-B, Lee S-i., et al. Development and Validation of Novel Scoring System for the Prediction of Disease Recurrence Following Resection of Colorectal Liver Metastasis. Asian J Surg (2020) 43(2):438–46. 10.1016/j.asjsur.2019.06.001 - DOI - PubMed